|A pragmatic–explanatory continuum indicator summary (PRECIS): a tool to help trial designers|
KE Thorpe, M Zwarenstein, AD Oxman, S Treweek, CD Furberg, ...
Journal of clinical epidemiology 62 (5), 464-475, 2009
|Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer|
K Halkidou, L Gaughan, S Cook, HY Leung, DE Neal, CN Robson
The Prostate 59 (2), 177-189, 2004
|Evidence for overuse of medical services around the world|
S Brownlee, K Chalkidou, J Doust, AG Elshaug, P Glasziou, I Heath, ...
The Lancet 390 (10090), 156-168, 2017
|Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development|
K Halkidou, VJ Gnanapragasam, PB Mehta, IR Logan, ME Brady, S Cook, ...
Oncogene 22 (16), 2466-2477, 2003
|How to formulate research recommendations|
P Brown, K Brunnhuber, K Chalkidou, I Chalmers, M Clarke, M Fenton, ...
Bmj 333 (7572), 804-806, 2006
|Comparative effectiveness research and evidence‐based health policy: experience from four countries|
K Chalkidou, S Tunis, R Lopert, L Rochaix, PT Sawicki, M Nasser, B Xerri
The Milbank Quarterly 87 (2), 339-367, 2009
|The role for pragmatic randomized controlled trials (pRCTs) in comparative effectiveness research|
K Chalkidou, S Tunis, D Whicher, R Fowler, M Zwarenstein
Clinical trials 9 (4), 436-446, 2012
|Evidence-informed frameworks for cost-effective cancer care and prevention in low, middle, and high-income countries|
K Chalkidou, P Marquez, PK Dhillon, Y Teerawattananon, ...
The lancet oncology 15 (3), e119-e131, 2014
|Searching for cost effectiveness thresholds in the NHS|
J Appleby, N Devlin, D Parkin, M Buxton, K Chalkidou
Health policy 91 (3), 239-245, 2009
|Social values in health priority setting: a conceptual framework|
P Littlejohns, A Weale, K Chalkidou, Y Teerwattananon, R Faden, S Clark
Journal of health organization and management, 2012
|NCD Countdown 2030: worldwide trends in non-communicable disease mortality and progress towards Sustainable Development Goal target 3.4|
JE Bennett, GA Stevens, CD Mathers, R Bonita, J Rehm, ME Kruk, ...
The Lancet 392 (10152), 1072-1088, 2018
|Priority-setting in health: building institutions for smarter public spending|
A Glassman, K Chalkidou
Washington, DC: Center for Global Development, 2012
|Evidence-based decision making: when should we wait for more information?|
K Chalkidou, J Lord, A Fischer, P Littlejohns
Health Affairs 27 (6), 1642-1653, 2008
|Priority-setting institutions in health: recommendations from a center for global development working group|
A Glassman, K Chalkidou, U Giedion, Y Teerawattananon, S Tunis, ...
Global Heart 7 (1), 13-34, 2012
|Making a decision to wait for more evidence: when the National Institute for Health and Clinical Excellence recommends a technology only in the context of research|
K Chalkidou, A Hoy, P Littlejohns
Journal of the Royal Society of Medicine 100 (10), 453-460, 2007
|Nuclear accumulation of histone deacetylase 4 (HDAC4) coincides with the loss of androgen sensitivity in hormone refractory cancer of the prostate|
K Halkidou, S Cook, HY Leung, DE Neal, CN Robson
European urology 45 (3), 382-389, 2004
|Priority-setting for achieving universal health coverage|
K Chalkidou, A Glassman, R Marten, J Vega, Y Teerawattananon, ...
Bulletin of the World Health Organization 94 (6), 462, 2016
|Expensive cancer drugs: a comparison between the United States and the United Kingdom|
RR Faden, K Chalkidou, J Appleby, HR Waters, JP Leider
The Milbank Quarterly 87 (4), 789-819, 2009
|Putative involvement of the histone acetyltransferase Tip60 in ribosomal gene transcription|
K Halkidou, IR Logan, S Cook, DE Neal, CN Robson
Nucleic acids research 32 (5), 1654-1665, 2004
|Cost‐effective public health guidance: asking questions from the decision‐maker's viewpoint|
K Chalkidou, A Culyer, B Naidoo, P Littlejohns
Health economics 17 (3), 441-448, 2008